These results suggested that MTA2 may be a potential target for HCC immunotherapy due to the analyses of MTA2 with immune checkpoint genes and anti-PD-L1 immunotherapy in the IMvigor210 dataset. The gene discussed is MTA2; the disease is hepatocellular carcinoma.